Sabine Seiler

Offenbach, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Journal: Nature medicine

Published: January 20, 2026

Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.

Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.

Journal: Cancer cell

Published: April 26, 2024

Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification.

Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification.

Journal: NPJ breast cancer

Published: April 22, 2024

GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.

GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.

Journal: NPJ breast cancer

Published: March 13, 2024

Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy.

Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy.

Journal: Breast (Edinburgh, Scotland)

Published: January 03, 2024

Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study.

Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 07, 2023

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 14, 2023

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.

Journal: Breast (Edinburgh, Scotland)

Published: August 04, 2022

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.

Journal: JAMA oncology

Published: May 19, 2022

Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.

Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 04, 2022

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 01, 2021

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.

Journal: The Lancet. Oncology

Published: March 25, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026